CSPG4 and neoplasm: The melanoma xenograft model with CD20+ Mel526 tumor cells clearly demonstrated that treatment with CSPG4-CAR T cells led to continuous tumor outgrowth, while robust tumor regression was only achieved upon treatment with dual-specific CSPG4-CAR_CD20-CCR T cells.